GT Biopharma, Inc. (GTBP) 10-Year Financial Performance & Capital Metrics

GTBP • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsHematologic Oncology

AboutGT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I/II clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.Show more

Revenue $0
EBITDA -$13M
Net Income -$13M -73.3%
EPS (Diluted) -6.94 -23.0%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -453.39% -473.2%
ROIC -2583.45% -1510.0%
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Weak momentum: RS Rating 13 (bottom 13%)
✗Shares diluted 40.7% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM26.33%

EPS CAGR

10Y-

5Y-

3Y-

TTM50.6%

ROCE

10Y Avg-205.35%

5Y Avg-256.08%

3Y Avg-253.93%

Latest-494.8%

Peer Comparison

Hematologic Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
INCYIncyte Corporation	20.66B	105.24	701.60	14.76%	24.69%	25.55%	1.21%	0.01
TGTXTG Therapeutics, Inc.	4.88B	30.71	204.73	40.8%	13.31%	21.87%		1.14
AGIOAgios Pharmaceuticals, Inc.	1.62B	27.80	2.39	36.07%	-8.96%	-31.24%		0.04
CLRBCellectar Biosciences, Inc.	15.48M	3.65	-0.09			-200.99%		0.03
CASICASI Pharmaceuticals, Inc.	21.37M	1.04	-0.41	-15.77%	-183.93%	-301.8%		11.96
VORVor Biopharma Inc.	308.06M	14.06	-0.41			-94.52%		0.33
FATEFate Therapeutics, Inc.	121.12M	1.05	-0.64	-78.55%	-21.87%	-66.69%		0.27
KPTIKaryopharm Therapeutics Inc.	121.95M	6.66	-0.71	-0.55%	-87.43%

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	27K	0	0	0	0	0	0	0	0	0
Revenue Growth %	-0.56%	-1%	-	-	-	-	-	-	-	-
Cost of Goods Sold+	2K	1K	2K	7K	4K	0	0	0	0	0
COGS % of Revenue	0.07%	-	-	-	-	-	-	-	-	-
Gross Profit+	25K	-1K	-2K	-7K	-4K	0	0	0	0	0
Gross Margin %	0.93%	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	5.25%	-1.04%	-1%	-2.5%	0.43%	1%	-	-	-	-
Operating Expenses+	8.95M	9.37M	135.57M	21.55M	11.45M	6.76M	57.52M	21.26M	13.58M	14.36M
OpEx % of Revenue	331.63%	-	-	-	-	-	-	-	-	-
Selling, General & Admin	7.95M	8.4M	134.5M	12.49M	9.79M	6.28M	47.92M	12.45M	7.11M	8.57M
SG&A % of Revenue	294.59%	-	-	-	-	-	-	-	-	-
Research & Development	1M	975K	1.07M	9.07M	1.67M	485K	9.59M	8.81M	6.47M	5.8M
R&D % of Revenue	37.04%	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income+	-8.93M	-9.37M	-135.57M	-250.07M	-11.46M	-6.76M	-57.52M	-21.26M	-13.58M	-14.36M
Operating Margin %	-330.63%	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-2.73%	-0.05%	-13.46%	-0.84%	0.95%	0.41%	-7.5%	0.63%	0.36%	-0.06%
EBITDA+	-8.93M	-9.37M	-135.57M	-250.06M	-11.45M	-6.76M	-57.48M	-20.96M	0	-13.16M
EBITDA Margin %	-330.56%	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-2.76%	-0.05%	-13.46%	-0.84%	0.95%	0.41%	-7.5%	0.64%	1%	-
D&A (Non-Cash Add-back)	2K	1K	2K	7K	4K	4K	0	0	13.58M	0
EBIT	-8.93M	-9.37M	-135.57M	-250.07M	-36.52M	-24.98M	-57.54M	-20.88M	-7.6M	-13.16M
Net Interest Income+	-17.04M	-6.55M	-8.6M	-9.12M	-2.13M	-3.32M	-680K	284K	567K	402K
Interest Income	0	0	0	0	2.13K	3.32K	38K	292K	780K	402K
Interest Expense	17.04M	6.55M	8.6M	9.12M	2.13M	3.32M	718K	8K	213K	0
Other Income/Expense	-12.53M	19.14M	-8.6M	-9.12M	-27.19M	-21.53M	-498K	373K	5.98M	1.2M
Pretax Income+	-21.46M	9.77M	-144.17M	-259.19M	-38.65M	-28.3M	-58.01M	-20.88M	-7.6M	-13.16M
Pretax Margin %	-794.85%	-	-	-	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-21.46M	9.77M	-144.17M	-259.19M	-38.65M	-28.3M	-58.01M	-20.88M	-7.6M	-13.16M
Net Margin %	-794.85%	-	-	-	-	-	-	-	-	-
Net Income Growth %	0.09%	1.46%	-15.76%	-0.8%	0.85%	0.27%	-1.05%	0.64%	0.64%	-0.73%
Net Income (Continuing)	-21.46M	9.77M	-144.17M	-259.19M	-38.65M	-28.3M	-58.01M	-20.88M	-7.6M	-13.16M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	-169K	-169K	-169K	-169K	-169K	-169K	0	0	0	0
EPS (Diluted)+	-999999.00	61200.00	-145.22	-87.70	-11.42	-6.45	-2.06	-0.66	-5.64	-6.94
EPS Growth %	0.09%	1.04%	-1%	0.4%	0.87%	0.44%	0.68%	0.68%	-7.55%	-0.23%
EPS (Basic)	-999999.00	61200.00	-145.22	-87.70	-11.42	-6.45	-2.06	-0.66	-5.64	-6.94
Diluted Shares Outstanding	15	160	986.42K	2.96M	3.38M	4.38M	28.16M	31.87M	1.35M	1.9M
Basic Shares Outstanding	15	160	986.42K	2.96M	3.38M	4.38M	28.16M	31.87M	1.35M	1.9M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	49K	21K	576K	90K	274K	5.66M	32.17M	16.56M	14.06M	4.23M
Cash & Short-Term Investments	47K	19K	576K	60K	28K	5.3M	31.98M	16.51M	13.97M	3.95M
Cash Only	47K	19K	576K	60K	28K	5.3M	8.97M	5.67M	1.08M	3.95M
Short-Term Investments	0	0	0	0	0	0	23.01M	10.84M	12.89M	0
Accounts Receivable	0	0	0	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	0	0	0	0	0	281K
Total Non-Current Assets+	5K	4K	253.79M	25.31M	122K	0	0	174K	53K	0
Property, Plant & Equipment	5K	4K	6K	35K	110K	0	0	165K	53K	0
Fixed Asset Turnover	5.40x	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	253.78M	25.26M	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	0	9K	12K	12K	0	0	9K	0	0
Total Assets+	54K	25K	254.37M	25.4M	396K	5.66M	32.17M	16.74M	14.11M	4.23M
Asset Turnover	0.50x	-	-	-	-	-	-	-	-	-
Asset Growth %	-0.94%	-0.54%	10173.72%	-0.9%	-0.98%	13.3%	4.68%	-0.48%	-0.16%	-0.7%
Total Current Liabilities+	49.91M	18.95M	2.68M	14.03M	19.71M	35.09M	10.26M	4.94M	6.63M	5.9M
Accounts Payable	893K	2.1M	2.55M	1.76M	1.94M	2.24M	8.19M	3.14M	4.33M	3.85M
Days Payables Outstanding	162.97K	766.5K	464.64K	91.88K	177.03K	-	-	-	-	-
Short-Term Debt	9.03M	12.41M	31K	10.8M	13.24M	26.33M	31K	0	0	0
Deferred Revenue (Current)	1000K	1000K	0	0	0	1000K	1000K	0	0	0
Other Current Liabilities	26.55M	-3.6M	1K	8K	0	-5.75M	-1.76M	19K	1.05M	252K
Current Ratio	0.00x	0.00x	0.22x	0.01x	0.01x	0.16x	3.14x	3.35x	2.12x	0.72x
Quick Ratio	0.00x	0.00x	0.22x	0.01x	0.01x	0.16x	3.14x	3.35x	2.12x	0.72x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	714K	0	0	0	0	0	0	64K	0	0
Long-Term Debt	714K	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	64K	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0	0	0
Total Liabilities	50.62M	18.95M	2.68M	14.03M	19.71M	35.09M	10.26M	5M	6.63M	5.9M
Total Debt+	9.75M	12.41M	31K	10.8M	13.36M	26.33M	31K	174K	58K	0
Net Debt	9.7M	12.39M	-545K	10.74M	13.33M	21.04M	-8.94M	-5.5M	-1.02M	-3.95M
Debt / Equity	-	-	0.00x	0.95x	-	-	0.00x	0.01x	0.01x	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-0.52x	-1.43x	-15.76x	-27.43x	-5.38x	-2.04x	-80.10x	-2657.13x	-63.74x	-
Total Equity+	-50.57M	-18.92M	251.69M	11.37M	-19.31M	-29.43M	21.91M	11.73M	7.48M	-1.67M
Equity Growth %	-0.71%	0.63%	14.3%	-0.95%	-2.7%	-0.52%	1.74%	-0.46%	-0.36%	-1.22%
Book Value per Share	-999999.00	-118527.23	255.15	3.85	-5.70	-6.71	0.78	0.37	5.55	-0.88
Total Shareholders' Equity	-50.4M	-18.75M	251.86M	11.54M	-19.14M	-29.26M	21.91M	11.73M	7.48M	-1.67M
Common Stock	2K	31K	50K	51K	70K	52K	1.15M	33K	1K	2K
Retained Earnings	-134.42M	-124.65M	-269.5M	-528.68M	-567.33M	-595.63M	-653.58M	-674.47M	-682.07M	-695.23M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	0	0	1.11M	0	0	0
Minority Interest	-169K	-169K	-169K	-169K	-169K	-169K	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-4.66M	-1.93M	-5.43M	-10.68M	-3.66M	-7.26M	-15.61M	-15.22M	-8.85M	-12.9M
Operating CF Margin %	-172.48%	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-1.66%	0.59%	-1.81%	-0.97%	0.66%	-0.98%	-1.15%	0.02%	0.42%	-0.46%
Net Income	-32.73M	21.03M	-143.25M	-259.19M	-38.65M	-28.3M	-58.01M	-20.88M	-7.6M	-13.16M
Depreciation & Amortization	2K	1K	2K	7K	4K	0	0	0	0	0
Stock-Based Compensation	3.76M	6.59M	130.12M	9.7M	5.31M	269K	33.93M	7.65M	2.2M	230K
Deferred Taxes	9.89M	-34.06M	4.91M	228.51M	0	0	0	0	0	0
Other Non-Cash Items	13.51M	1.7M	1.37M	10.18M	25.6M	18.36M	538K	10K	-5.28M	-800K
Working Capital Changes	905K	2.81M	1.41M	111K	4.08M	2.4M	7.94M	-1.99M	1.82M	828K
Change in Receivables	1.11M	0	0	0	0	0	0	0	0	0
Change in Inventory	42K	0	0	0	0	0	0	0	0	0
Change in Payables	-276K	880K	1.41M	136K	3.15M	-838K	7.08M	-2.03M	1.96M	937K
Cash from Investing+	-1K	-1K	-4K	-36K	200K	0	-23.04M	12.14M	-2.01M	12.89M
Capital Expenditures	-1K	0	-4K	-36K	0	0	0	0	0	0
CapEx % of Revenue	0.04%	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	-1K	0	0	200K	0	0	-12.14M	-2.01M	0
Cash from Financing+	3.85M	1.9M	5.99M	10.2M	3.43M	12.53M	42.32M	-224K	6.27M	2.98M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	0	0	-533K	0	0	16.43M	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-4.66M	-1.93M	-5.43M	-10.71M	-3.66M	-7.26M	-15.61M	-15.22M	-8.85M	-12.9M
FCF Margin %	-172.52%	-	-	-	-	-	-	-	-	-
FCF Growth %	-1.65%	0.59%	-1.82%	-0.97%	0.66%	-0.98%	-1.15%	0.02%	0.42%	-0.46%
FCF per Share	-310533.33	-12088.22	-5.51	-3.63	-1.08	-1.66	-0.55	-0.48	-6.57	-6.80
FCF Conversion (FCF/Net Income)	0.22x	-0.20x	0.04x	0.04x	0.09x	0.26x	0.27x	0.73x	1.17x	0.98x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-123.88%	-197.06%	-	-	-264.78%	-124.15%	-79.09%	-453.39%
Return on Invested Capital (ROIC)	-	-	-83.13%	-137.27%	-106.52%	-	-1884.91%	-165.99%	-160.46%	-2583.45%
Gross Margin	92.59%	-	-	-	-	-	-	-	-	-
Net Margin	-79485.19%	-	-	-	-	-	-	-	-	-
Debt / Equity	-	-	0.00x	0.95x	-	-	0.00x	0.01x	0.01x	-
Interest Coverage	-0.52x	-1.43x	-15.76x	-27.43x	-5.38x	-2.04x	-80.10x	-2657.13x	-63.74x	-
FCF Conversion	0.22x	-0.20x	0.04x	0.04x	0.09x	0.26x	0.27x	0.73x	1.17x	0.98x
Revenue Growth	-55.74%	-100%	-	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

GT Biopharma, Inc. (GTBP) grew revenue by 0.0% over the past year. Growth has been modest.

GT Biopharma, Inc. (GTBP) reported a net loss of $9.1M for fiscal year 2024.

Dividend & Returns

GT Biopharma, Inc. (GTBP) has a return on equity (ROE) of -453.4%. Negative ROE indicates the company is unprofitable.

GT Biopharma, Inc. (GTBP) had negative free cash flow of $11.4M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

GT Biopharma, Inc. (GTBP) 10-Year Financial Performance & Capital Metrics

GTBP • • Industrial / General

HealthcareBiotechnologyOncology TherapeuticsHematologic Oncology

Revenue $0
EBITDA -$13M
Net Income -$13M -73.3%
EPS (Diluted) -6.94 -23.0%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -453.39% -473.2%
ROIC -2583.45% -1510.0%
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

No significant strengths identified

✗Weaknesses

✗Weak Piotroski F-Score: 1/9
✗Weak momentum: RS Rating 13 (bottom 13%)
✗Shares diluted 40.7% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM26.33%

EPS CAGR

10Y-

5Y-

3Y-

TTM50.6%

ROCE

10Y Avg-205.35%

5Y Avg-256.08%

3Y Avg-253.93%

Latest-494.8%

Peer Comparison

Hematologic Oncology

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
INCYIncyte Corporation	20.66B	105.24	701.60	14.76%	24.69%	25.55%	1.21%	0.01
TGTXTG Therapeutics, Inc.	4.88B	30.71	204.73	40.8%	13.31%	21.87%		1.14
AGIOAgios Pharmaceuticals, Inc.	1.62B	27.80	2.39	36.07%	-8.96%	-31.24%		0.04
CLRBCellectar Biosciences, Inc.	15.48M	3.65	-0.09			-200.99%		0.03
CASICASI Pharmaceuticals, Inc.	21.37M	1.04	-0.41	-15.77%	-183.93%	-301.8%		11.96
VORVor Biopharma Inc.	308.06M	14.06	-0.41			-94.52%		0.33
FATEFate Therapeutics, Inc.	121.12M	1.05	-0.64	-78.55%	-21.87%	-66.69%		0.27
KPTIKaryopharm Therapeutics Inc.	121.95M	6.66	-0.71	-0.55%	-87.43%

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	27K	0	0	0	0	0	0	0	0	0
Revenue Growth %	-0.56%	-1%	-	-	-	-	-	-	-	-
Cost of Goods Sold+	2K	1K	2K	7K	4K	0	0	0	0	0
COGS % of Revenue	0.07%	-	-	-	-	-	-	-	-	-
Gross Profit+	25K	-1K	-2K	-7K	-4K	0	0	0	0	0
Gross Margin %	0.93%	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	5.25%	-1.04%	-1%	-2.5%	0.43%	1%	-	-	-	-
Operating Expenses+	8.95M	9.37M	135.57M	21.55M	11.45M	6.76M	57.52M	21.26M	13.58M	14.36M
OpEx % of Revenue	331.63%	-	-	-	-	-	-	-	-	-
Selling, General & Admin	7.95M	8.4M	134.5M	12.49M	9.79M	6.28M	47.92M	12.45M	7.11M	8.57M
SG&A % of Revenue	294.59%	-	-	-	-	-	-	-	-	-
Research & Development	1M	975K	1.07M	9.07M	1.67M	485K	9.59M	8.81M	6.47M	5.8M
R&D % of Revenue	37.04%	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	0	0	0	0	0	0
Operating Income+	-8.93M	-9.37M	-135.57M	-250.07M	-11.46M	-6.76M	-57.52M	-21.26M	-13.58M	-14.36M
Operating Margin %	-330.63%	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-2.73%	-0.05%	-13.46%	-0.84%	0.95%	0.41%	-7.5%	0.63%	0.36%	-0.06%
EBITDA+	-8.93M	-9.37M	-135.57M	-250.06M	-11.45M	-6.76M	-57.48M	-20.96M	0	-13.16M
EBITDA Margin %	-330.56%	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-2.76%	-0.05%	-13.46%	-0.84%	0.95%	0.41%	-7.5%	0.64%	1%	-
D&A (Non-Cash Add-back)	2K	1K	2K	7K	4K	4K	0	0	13.58M	0
EBIT	-8.93M	-9.37M	-135.57M	-250.07M	-36.52M	-24.98M	-57.54M	-20.88M	-7.6M	-13.16M
Net Interest Income+	-17.04M	-6.55M	-8.6M	-9.12M	-2.13M	-3.32M	-680K	284K	567K	402K
Interest Income	0	0	0	0	2.13K	3.32K	38K	292K	780K	402K
Interest Expense	17.04M	6.55M	8.6M	9.12M	2.13M	3.32M	718K	8K	213K	0
Other Income/Expense	-12.53M	19.14M	-8.6M	-9.12M	-27.19M	-21.53M	-498K	373K	5.98M	1.2M
Pretax Income+	-21.46M	9.77M	-144.17M	-259.19M	-38.65M	-28.3M	-58.01M	-20.88M	-7.6M	-13.16M
Pretax Margin %	-794.85%	-	-	-	-	-	-	-	-	-
Income Tax+	0	0	0	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-21.46M	9.77M	-144.17M	-259.19M	-38.65M	-28.3M	-58.01M	-20.88M	-7.6M	-13.16M
Net Margin %	-794.85%	-	-	-	-	-	-	-	-	-
Net Income Growth %	0.09%	1.46%	-15.76%	-0.8%	0.85%	0.27%	-1.05%	0.64%	0.64%	-0.73%
Net Income (Continuing)	-21.46M	9.77M	-144.17M	-259.19M	-38.65M	-28.3M	-58.01M	-20.88M	-7.6M	-13.16M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	-169K	-169K	-169K	-169K	-169K	-169K	0	0	0	0
EPS (Diluted)+	-999999.00	61200.00	-145.22	-87.70	-11.42	-6.45	-2.06	-0.66	-5.64	-6.94
EPS Growth %	0.09%	1.04%	-1%	0.4%	0.87%	0.44%	0.68%	0.68%	-7.55%	-0.23%
EPS (Basic)	-999999.00	61200.00	-145.22	-87.70	-11.42	-6.45	-2.06	-0.66	-5.64	-6.94
Diluted Shares Outstanding	15	160	986.42K	2.96M	3.38M	4.38M	28.16M	31.87M	1.35M	1.9M
Basic Shares Outstanding	15	160	986.42K	2.96M	3.38M	4.38M	28.16M	31.87M	1.35M	1.9M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	49K	21K	576K	90K	274K	5.66M	32.17M	16.56M	14.06M	4.23M
Cash & Short-Term Investments	47K	19K	576K	60K	28K	5.3M	31.98M	16.51M	13.97M	3.95M
Cash Only	47K	19K	576K	60K	28K	5.3M	8.97M	5.67M	1.08M	3.95M
Short-Term Investments	0	0	0	0	0	0	23.01M	10.84M	12.89M	0
Accounts Receivable	0	0	0	0	0	0	0	0	0	0
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	0	0	0	0	0	0	0	0	0	281K
Total Non-Current Assets+	5K	4K	253.79M	25.31M	122K	0	0	174K	53K	0
Property, Plant & Equipment	5K	4K	6K	35K	110K	0	0	165K	53K	0
Fixed Asset Turnover	5.40x	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	253.78M	25.26M	0	0	0	0	0	0
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	0	0	9K	12K	12K	0	0	9K	0	0
Total Assets+	54K	25K	254.37M	25.4M	396K	5.66M	32.17M	16.74M	14.11M	4.23M
Asset Turnover	0.50x	-	-	-	-	-	-	-	-	-
Asset Growth %	-0.94%	-0.54%	10173.72%	-0.9%	-0.98%	13.3%	4.68%	-0.48%	-0.16%	-0.7%
Total Current Liabilities+	49.91M	18.95M	2.68M	14.03M	19.71M	35.09M	10.26M	4.94M	6.63M	5.9M
Accounts Payable	893K	2.1M	2.55M	1.76M	1.94M	2.24M	8.19M	3.14M	4.33M	3.85M
Days Payables Outstanding	162.97K	766.5K	464.64K	91.88K	177.03K	-	-	-	-	-
Short-Term Debt	9.03M	12.41M	31K	10.8M	13.24M	26.33M	31K	0	0	0
Deferred Revenue (Current)	1000K	1000K	0	0	0	1000K	1000K	0	0	0
Other Current Liabilities	26.55M	-3.6M	1K	8K	0	-5.75M	-1.76M	19K	1.05M	252K
Current Ratio	0.00x	0.00x	0.22x	0.01x	0.01x	0.16x	3.14x	3.35x	2.12x	0.72x
Quick Ratio	0.00x	0.00x	0.22x	0.01x	0.01x	0.16x	3.14x	3.35x	2.12x	0.72x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	714K	0	0	0	0	0	0	64K	0	0
Long-Term Debt	714K	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	0	0	64K	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0	0	0	0
Total Liabilities	50.62M	18.95M	2.68M	14.03M	19.71M	35.09M	10.26M	5M	6.63M	5.9M
Total Debt+	9.75M	12.41M	31K	10.8M	13.36M	26.33M	31K	174K	58K	0
Net Debt	9.7M	12.39M	-545K	10.74M	13.33M	21.04M	-8.94M	-5.5M	-1.02M	-3.95M
Debt / Equity	-	-	0.00x	0.95x	-	-	0.00x	0.01x	0.01x	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-0.52x	-1.43x	-15.76x	-27.43x	-5.38x	-2.04x	-80.10x	-2657.13x	-63.74x	-
Total Equity+	-50.57M	-18.92M	251.69M	11.37M	-19.31M	-29.43M	21.91M	11.73M	7.48M	-1.67M
Equity Growth %	-0.71%	0.63%	14.3%	-0.95%	-2.7%	-0.52%	1.74%	-0.46%	-0.36%	-1.22%
Book Value per Share	-999999.00	-118527.23	255.15	3.85	-5.70	-6.71	0.78	0.37	5.55	-0.88
Total Shareholders' Equity	-50.4M	-18.75M	251.86M	11.54M	-19.14M	-29.26M	21.91M	11.73M	7.48M	-1.67M
Common Stock	2K	31K	50K	51K	70K	52K	1.15M	33K	1K	2K
Retained Earnings	-134.42M	-124.65M	-269.5M	-528.68M	-567.33M	-595.63M	-653.58M	-674.47M	-682.07M	-695.23M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	0	0	0	0	0	0	1.11M	0	0	0
Minority Interest	-169K	-169K	-169K	-169K	-169K	-169K	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-4.66M	-1.93M	-5.43M	-10.68M	-3.66M	-7.26M	-15.61M	-15.22M	-8.85M	-12.9M
Operating CF Margin %	-172.48%	-	-	-	-	-	-	-	-	-
Operating CF Growth %	-1.66%	0.59%	-1.81%	-0.97%	0.66%	-0.98%	-1.15%	0.02%	0.42%	-0.46%
Net Income	-32.73M	21.03M	-143.25M	-259.19M	-38.65M	-28.3M	-58.01M	-20.88M	-7.6M	-13.16M
Depreciation & Amortization	2K	1K	2K	7K	4K	0	0	0	0	0
Stock-Based Compensation	3.76M	6.59M	130.12M	9.7M	5.31M	269K	33.93M	7.65M	2.2M	230K
Deferred Taxes	9.89M	-34.06M	4.91M	228.51M	0	0	0	0	0	0
Other Non-Cash Items	13.51M	1.7M	1.37M	10.18M	25.6M	18.36M	538K	10K	-5.28M	-800K
Working Capital Changes	905K	2.81M	1.41M	111K	4.08M	2.4M	7.94M	-1.99M	1.82M	828K
Change in Receivables	1.11M	0	0	0	0	0	0	0	0	0
Change in Inventory	42K	0	0	0	0	0	0	0	0	0
Change in Payables	-276K	880K	1.41M	136K	3.15M	-838K	7.08M	-2.03M	1.96M	937K
Cash from Investing+	-1K	-1K	-4K	-36K	200K	0	-23.04M	12.14M	-2.01M	12.89M
Capital Expenditures	-1K	0	-4K	-36K	0	0	0	0	0	0
CapEx % of Revenue	0.04%	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	-1K	0	0	200K	0	0	-12.14M	-2.01M	0
Cash from Financing+	3.85M	1.9M	5.99M	10.2M	3.43M	12.53M	42.32M	-224K	6.27M	2.98M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	0	0	0	-533K	0	0	16.43M	0	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-4.66M	-1.93M	-5.43M	-10.71M	-3.66M	-7.26M	-15.61M	-15.22M	-8.85M	-12.9M
FCF Margin %	-172.52%	-	-	-	-	-	-	-	-	-
FCF Growth %	-1.65%	0.59%	-1.82%	-0.97%	0.66%	-0.98%	-1.15%	0.02%	0.42%	-0.46%
FCF per Share	-310533.33	-12088.22	-5.51	-3.63	-1.08	-1.66	-0.55	-0.48	-6.57	-6.80
FCF Conversion (FCF/Net Income)	0.22x	-0.20x	0.04x	0.04x	0.09x	0.26x	0.27x	0.73x	1.17x	0.98x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-	-	-123.88%	-197.06%	-	-	-264.78%	-124.15%	-79.09%	-453.39%
Return on Invested Capital (ROIC)	-	-	-83.13%	-137.27%	-106.52%	-	-1884.91%	-165.99%	-160.46%	-2583.45%
Gross Margin	92.59%	-	-	-	-	-	-	-	-	-
Net Margin	-79485.19%	-	-	-	-	-	-	-	-	-
Debt / Equity	-	-	0.00x	0.95x	-	-	0.00x	0.01x	0.01x	-
Interest Coverage	-0.52x	-1.43x	-15.76x	-27.43x	-5.38x	-2.04x	-80.10x	-2657.13x	-63.74x	-
FCF Conversion	0.22x	-0.20x	0.04x	0.04x	0.09x	0.26x	0.27x	0.73x	1.17x	0.98x
Revenue Growth	-55.74%	-100%	-	-	-	-	-	-	-	-

Frequently Asked Questions

Growth & Financials

GT Biopharma, Inc. (GTBP) grew revenue by 0.0% over the past year. Growth has been modest.

GT Biopharma, Inc. (GTBP) reported a net loss of $9.1M for fiscal year 2024.

Dividend & Returns

GT Biopharma, Inc. (GTBP) has a return on equity (ROE) of -453.4%. Negative ROE indicates the company is unprofitable.

GT Biopharma, Inc. (GTBP) had negative free cash flow of $11.4M in fiscal year 2024, likely due to heavy capital investments.